Cellyan Biotechnology Co Ltd (HKPD) FinancialsHKPDCellyan Biotechnology Co Ltd

Evaluating the bottom line, Cellyan Biotechnology Co Ltd maintains a gross margin of 10.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.47%, while the net margin is -8.46%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HKPD converts its operational activities into shareholder value.

In the context of the broader market, HKPD competes directly with industry leaders such as CJMB and GVH. With a market capitalization of $3.58M, it holds a leading position in the sector. When comparing efficiency, HKPD's gross margin of 10.32% stands against CJMB's 55.07% and GVH's 7.07%. Such benchmarking helps identify whether Cellyan Biotechnology Co Ltd is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of only 13.04% in the latest quarter, with consistent net losses, including a net income of -427808 USD in Q1 2026. The total debt is decreasing, but the overall financial health remains concerning.